BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

NCT02054481 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: BI 655066
DRUG: BI 655066
DRUG: Ustekinumab
DRUG: BI 655066

Sponsor

Boehringer Ingelheim